Evidence Regarding Pharmacogenetics in Pain Management and Cancer

Abstract Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2023-03, Vol.28 (3), p.189-192
Hauptverfasser:	Smith, D Max, Figg, William D
Format:	Artikel
Sprache:	eng
Schlagworte:	Analgesics, Opioid - therapeutic use Analysis Cancer pain Cancer Pain - drug therapy Cancer Pain - genetics Care and treatment Catechol O-Methyltransferase - genetics Catechol O-Methyltransferase - therapeutic use Commentaries Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP2D6 - therapeutic use Evaluation Evidence-based medicine Genetic aspects Genotype Humans Morphine - therapeutic use Neoplasms - drug therapy Neoplasms - genetics Oxycodone - therapeutic use Pain Management Pharmacogenetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics. Highlighting a recently published trial on COMT genotype and opioid dose requirements, this commentary describes the potential role for COMT and other genes (e.g., CYP2D6) on opioid therapy and current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.
ISSN:	1083-7159 1549-490X
DOI:	10.1093/oncolo/oyac277